Peter Coleman, former CEO, Cobra Biologics, commented on the announcement: “The organisations within the consortium led by the Jenner Institute are experts from across industry and academia, with the experience, capability and conviction to deliver a successful outcome. Cobra is privileged to have been invited to participate and contribute to the fight against COVID-19, as this virus continues to impact the globe exponentially.”
The first human clinical trials commenced in April and shortly thereafter AstraZeneca announced its in-licensed programme with the University of Oxford to ensure broad and equitable supply of the vaccine throughout the world, at no profit during the COVID-19 pandemic. In June, Cobra signed a supply agreement with AstraZeneca to provide GMP manufacture of the adenovirus vector-based COVID-19 vaccine candidate AZD1222 (previously known as ChAdOx1 n-CoV-19).
By November the efficacy data was announced and on the 30th December 2020 the MHRA officially gave the green light to the vaccine to be rolled out in January 2021.
What a year for science
Prof. Daniel Smith, Executive Director, Global Cell & Gene Therapy Portfolio Strategy, Cobra Biologics reflects: "What a year for science. My word for the year has been collaboration – everyone has worked together and has had a common goal. It has been a race against the virus, not against each other."